Glomerular diseases: Membranous nephropathy-a modern view

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 609-616

  Ponticelli, Claudio ^a   Glassock, Richard J ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CORTICOTROPIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPASE A2 RECEPTOR; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; INFECTION RISK; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM SURVIVAL; MEMBRANOUS GLOMERULONEPHRITIS; REMISSION; TREATMENT RESPONSE;

AUTOANTIBODIES; BIOLOGICAL MARKERS; BIOPSY; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84896897793     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04160413     Document Type: Article

References (54)

1. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
2. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616-626, 2011
3. Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, Boland-Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, Ronco P: Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol 24: 677-683, 2013
4. Salant DJ: Genetic variants in membranous nephropathy: Perhaps a perfect storm rather than a straightforward conformeropathy? J Am Soc Nephrol 24: 525-528, 2013
5. Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A, Bruno F, Radice A, Furci L, Argentiero L, Carnevali ML, Messa P, Scolari F, Sinico RA, Gesualdo L, Fervenza FC, Allegri L, Ravani P, Ghiggeri GM: Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 7: 1394-1400, 2012
6. Glassock RJ: Secondary membranous glomerulonephritis. Nephrol Dial Transplant 7[SUPPL. 1]: 64-71, 1992
7. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA: Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82: 797-804, 2012
8. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z: Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22: 1137-1143, 2011
9. Alexander MP, Larsen CP, Gibson IW, Nasr SH, Sethi S, Fidler ME, Raissian Y, Takahashi N, Chari S, Smyrk TC, Cornell LD: Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int 83: 455-462, 2013
10. Qu Z, Liu G, Li J, Wu LH, Tan Y, Zheng X, Ao J, Zhao MH: Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 27: 1931-1937, 2012
11. Jennette JC, Iskandar SS, Dalldorf FG: Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 24: 377-385, 1983
12. Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J; GN-PROGRESS Study Group: Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 70: 1510-1517, 2006
13. Segal PE, Choi MJ: Recent advances and prognosis in idiopathic membranous nephropathy. Adv Chronic Kidney Dis 19: 114-119, 2012
14. Lai KN, Li PK, Lui SF, Au TC, Tam JS, Tong KL, Lai FM: Membranous nephropathy related to hepatitis B virus in adults.NEngl J Med 324: 1457-1463, 1991
15. Zheng XY, Wei RB, Tang L, Li P, Zheng XD: Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 18: 821-832, 2012
16. Radford MG Jr, Holley KE, Grande JP, Larson TS, Wagoner RD, Donadio JV, McCarthy JT: Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 276: 466-469, 1996
17. Forslund T, Kellokumpu I, Elomaa E, Arola J, Nuorva K: Remission of membranous glomerulonephritis after pancreatectomy for pancreatic neuroendocrine neoplasm - a rare coincidence. Clin Nephrol 75[Suppl 1]: 42-46, 2011
18. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993
19. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Españ ola de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
20. Hladunewich MA, Troyanov S, Calafati J, Cattran DC; Metropolitan Toronto Glomerulonephritis Registry: The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 4: 1417-1422, 2009
21. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901-907, 1997
22. Beck LH Jr, Salant DJ: Membranous nephropathy: Recent travels and new roads ahead. Kidney Int 77: 765-770, 2010
23. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ: Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286-1291, 2011
24. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximabinduced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
25. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66: 1199-1205, 2004
26. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome: A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 301: 1301-1306, 1979
27. Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320: 210-215, 1989
28. Cameron JS, Healy MJ, Adu D; The MRC Glomerulonephritis Working Party: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med 74: 133-156, 1990
29. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, Sasdelli M, Locatelli F: Controlled trial ofmethylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310: 946-950, 1984
30. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sasdelli M, Locatelli F: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13, 1989
31. Ponticelli C, Zucchelli P, Passerini P, Cesana B; The Italian Idiopathic Membranous Nephropathy Treatment Study Group: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 327: 599-603, 1992
32. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998
33. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007
34. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, Bizzarri D, Banfi G: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
35. Kidney Disease Improving Global Outcomes: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2: 139-172, 2012
36. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N: Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 72: 1429-1447, 2007
37. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropati ́ía Membranosa: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71: 924-930, 2007
38. Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, Villar E, Pouteil-Noble C, Karaaslan H, Sichez H, Lasseur C, Delmas Y, Nogier MB, Fathallah M, Loundou A, Mayor V, Berland Y: Mycophenolate mofetil monotherapy in membranous nephropathy: A 1-year randomized controlled trial. Am J Kidney Dis 52: 699-705, 2008
39. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248-256, 2007
40. Chan TM, Lin AW, Tang SC, Qian JQ, Lam MF, Ho YW, Tse KC, Chan KW, Lai KN, Tang CS: Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 12: 576-581, 2007
41. Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, Sakhuja V, Jha V: Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol Dial Transplant 23: 1926-1930, 2008
42. Berg AL, Nilsson-Ehle P, Arnadottir M: Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 56: 1534-1543, 1999
43. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, Mandolfo S, Messa P: A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47: 233-240, 2006
44. Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB: type=contributor Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: A prospective trial.AmJ Nephrol 36: 58-67, 2012
45. Lindskog A, Ebefors K, Johansson ME, Stefánsson B, Granqvist A, Arnadottir M, Berg AL, Nyström J, Haraldsson B: Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 21: 1290-1298, 2010
46. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
47. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasà M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. JAmSocNephrol 23: 1416-1425, 2012
48. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group: Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 5: 2188-2198, 2010
49. Mathieson PW, Turner AN, Maidment CG, Evans DJ, Rees AJ: Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 2: 869-872, 1988
50. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O'Donoghue D, Boulton-Jones M, Mathieson PW: Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial. Lancet 381: 744-751, 2013
51. Glassock RJ: Prophylactic anticoagulation in nephrotic syndrome: A clinical conundrum. J AmSocNephrol 18: 2221-2225, 2007
52. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN: Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7: 43-51, 2012
53. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN: Diseasespecific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 81: 190-195, 2012
54. Sarasin FP, Schifferli JA: Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45: 578-585, 1994